Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersOphthalmology Physician in Boston, MA
NPI: 1366483778Primary Practice Location
TUFTS MEDICAL CENTER
755 Washington St, Boston, MA
Primary Employer
Pratt Ophthalmology Associates Inc
tuftsmedicine.org
HQ Phone
Get M.D. Pedram's Phone Numberphone_androidMobile
Get M.D. Pedram's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 275 | 486 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 75 | 92 |
| 3 | 92132Imaging of front third of eye | 72 | 86 |
| 4 | 92014Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 32 | 33 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 32 | 35 |
Reduced Corneal Endothelial Cell Density in Patients With Dry Eye Disease.
Authors: Ujwala Saboo, Thomas Dohlman, Ahmad Kheirkhah
Publication Date: 2014-09-24
Topical Cryopreserved Amniotic Membrane and Umbilical Cord Eye Drops Promote Re-Epithelialization in a Murine Corneal Abrasion Model.
Authors: Sean Tighe, Hamid-reza Moein, Lorraine Chua, Anny Cheng, Pedram Hamrah, Scheffer C Tseng
Publication Date: 2017-03-14
Authors: Benjamin Strauss
Journal: Cornea
Lead Sponsor: Tufts Medical Center
Collaborators: Ocular Therapeutix, Inc.
Intervention / Treatment: DRUG: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg), OTHER: ProLong™ collagen plugs
Lead Sponsor: Tufts Medical Center
Intervention / Treatment: DEVICE: TrueTear™ intranasal neurostimulator (ITN)
Lead Sponsor: Oyster Point Pharma, Inc.
Intervention / Treatment: DRUG: OC-01 (varenicline) nasal spray, DRUG: Placebo (vehicle control) nasal spray
